A Registry Study of Sanwujiaowan Capsule Used in Clinical Real World

Last updated: June 18, 2017
Sponsor: Yanming Xie
Overall Status: Trial Status Unknown

Phase

N/A

Condition

Pain

Collagen Vascular Diseases

Osteoarthritis

Treatment

N/A

Clinical Study ID

NCT03192787
Sanwujiaowan
  • All Genders

Study Summary

The purpose of this study is get to know what and how Sanwujiaowan capsule in hospital results in drug-induced liver injury or adverse drug reactions from a cohort event monitoring as registration research.

Eligibility Criteria

Inclusion

Inclusion Criteria: Patients using Sanwujiaowan capsule 's with abnormal liver function before medication fromJune 2017 to December 2018.

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 3000
Study Start date:
June 19, 2017
Estimated Completion Date:
December 31, 2018

Study Description

In order to improving monitoring drug-induced liver injury or adverse drug reactions of Chinese medicine containing Radix Polygoni Multiflori in hospital, registry study is suitable method in this area. Otherwise, nested case control study is used to find out the mechanism of drug-induced liver injury. Calculate the incidence of drug-induced liver injury or adverse drug reactions is one of the main aims for this study. Safety surveillance on Chinese medicine containing Radix Polygoni Multiflori is an important problem that needs to be sorted out through large sample observational study. According to the relevant regulations of the CFDA, 3000 cases need to be registered at least. The aim population is who using Sanwujiaowan capsule 's with abnormal liver function before medication from June 2017 to December 2018.